1LEUCHT S, WAHLBECK K, HAMANN J, et al. New generation antipsychotics versus tow-potency conventional antipsychotlcs: a systematic review and meta-analysis [J]. Lancet, 2003, 361 (1):1581-1589.
2LEUCHT S, BARNES T R, KISSLING W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics : a systematic review and exploratory meta-analysis of randomized, controlled trials [J]. Am J Psychiatry, 2003, 160 (7): 1209-1222.
3DAVIS J M, CHEN N, GLICK I D. A meta-analysis of the efficacy of second-generation antipsychotics [J]. Arch Gen Psychiatry, 2003, 60 (6) : 553-564.
4CORRELL C U, LEUCHT S, KANE J M. Lower risk for tardive dyskinesla associated with second-generation antlpsychotics: a systematic review of 1-year studies [J]. Am J Psychiatry, 2004, 161 (3) : 414-425.
5BAGNALL A M, JONES L, GINNELLY L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia [J]. Health Technol Assess, 2003, 7 (13): 1-193.
6HENNEN J, BALDESSARINI R J. Suicidal risk during treatment with clozapine: a meta-analysis [ J]. Schizophr Res, 2005, 73 (2) : 139- 145.
7TARSY D, BALDESSARINI R J, TARAZI F I. Effects of newer antipsychotics on extrapyramidal functions[J]. CNS Drugs, 2002, 16 ( 1 ) : 23-45.
8ANANTH J, PARAMESWARAN S GUNATILAKE S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs [ J ]. J Clin Psychiatry, 2004, 65 (4): 464-470.
9HENNEN J, PERLIS R H, SACHS G, et al. Weight gain during treatment of bipolar Ⅰ patients with olanzapine [ J ]. J Clln Psychiatry, 2004, 65 (12):1679-1687.
10SAFER D J. A comparison of risperidone induced weight gain across the age span [J]. J Clin Psychopharmacol, 2004, 24 (3) : 429-436.
